Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3203877 | 1.00 | PKM (0.68) | PKML3MBTL1MAPTGLALMNA | |
| SCHEMBL21892100 | 0.86 | MAPT (0.58) | PKML3MBTL1MAPTGLALMNA | |
| SCHEMBL10895023 | 0.84 | SIRT2 (0.57) | PKML3MBTL1MAPTLMNATP53 | |
| SCHEMBL8358198 | 0.84 | LPAR1 (0.75) | PKML3MBTL1MAPTGLALMNA | |
| SCHEMBL17680839 | 0.83 | ALDH1A1 (0.56) | PKML3MBTL1MAPTLMNATP53 | |
| SCHEMBL1232613 | 0.82 | PKM (0.61) | PKML3MBTL1MAPTGLANPC1 | |
| SCHEMBL1232614 | 0.82 | PKM (0.61) | PKML3MBTL1MAPTGLANPC1 | |
| SCHEMBL3590874 | 0.81 | MMP1 (0.74) | L3MBTL1MAPTLMNATP53NPC1 | |
| SCHEMBL13381249 | 0.81 | PKM (1.00) | PKML3MBTL1MAPTGLATP53 | |
| SCHEMBL3590876 | 0.81 | MMP1 (0.74) | L3MBTL1MAPTLMNATP53NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10624882-B2 | Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20160243102-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2016-08-25 | — | — | US | disclosed |
| US-20150297581-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2015-10-22 | — | — | US | disclosed |
| US-20140357652-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2014-12-04 | — | — | US | disclosed |
| US-8809326-B2 | Isoquinolinone Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20100056623-A1 | FUMAGILLOL DERIVATIVES OR METHOD FOR PREPARATION OF FUMAGILLOL DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2010-03-04 | — | — | US | disclosed |
| EP-1841761-A4 | FUMAGILLOL DERIVATIVES OR METHOD FOR PREPARATION OF FUMAGILLOL DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2008-10-29 | — | — | EP | disclosed |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ALCON INC. (CH) | 2008-07-03 | — | — | US | disclosed |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ALCON INC. (CH) | 2008-07-03 | — | — | US | disclosed |
| WO-2008036540-A2 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-03-27 | — | — | WO | disclosed |
| EP-1841761-A1 | FUMAGILLOL DERIVATIVES OR METHOD FOR PREPARATION OF FUMAGILLOL DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006080591-A1 | FUMAGILLOL DERIVATIVES OR METHOD FOR PREPARATION OF FUMAGILLOL DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2006-08-03 | — | — | WO | disclosed |
| EP-0938474-B1 | CYCLOPROPYLINDOLE COMPOUNDS AND THEIR USE AS PRODRUGS | AUCKLAND UNISERVICES LTD (NZ) | 2005-11-23 | — | — | EP | disclosed |
| EP-0944596-B1 | 1-ACRYLOYLINDOLINE DERIVATIVES AND THEIR USE AS PRODRUGS OF ANTICANCER AGENTS | AUCKLAND UNISERVICES LTD (NZ) | 2002-10-16 | — | — | EP | disclosed |
| US-6465485-B1 | SUCH AS 7-CYANO-2-(2-(1-(4-(2-INDOLYL)CARBOXAMIDO)CYCLO-HEXYL)ETHYL)-1,2,3,4 -TETRAHYDROISOQUINOLINE; ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-15 | — | — | US | disclosed |
| US-6251933-B1 | AMINO DERIVATIVES OF THE GENERAL CLASS OF CYCLOPROPYLINDOLES AND THEIR SECO PRECURSORS, AND USEFUL AS PRODRUG FOR ANTIBODY-DIRECTED ENZYME-PRODRUG THERAPY AND GENE-DIRECTED ENZYME-PRODRUG THERAPY FOR CANCER | THE CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2001-06-26 | — | — | US | disclosed |
| US-6143762-A | DRUGS AS DOPAMINE ANTAGONIST PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM, PLC (GB) | 2000-11-07 | — | — | US | disclosed |
| US-6130237-A | Condensed N-aclyindoles as antitumor agents | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056623-A1 | FUMAGILLOL DERIVATIVES OR METHOD FOR PREPARATION OF FUMAGILLOL DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | FAH, FH, ALDH1A2 | PKM 2043/4885L3MBTL1 3770/4885MAPT 638/4885 |
| US-20160243102-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | PKM 1453/4885L3MBTL1 3493/4885MAPT 1764/4885 |
| US-20150297581-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | PKM 1453/4885L3MBTL1 3493/4885MAPT 1764/4885 |
| US-10624882-B2 | Rho kinase inhibitors | ROCK1, ROCK2, CIT | PKM 1453/4885L3MBTL1 3493/4885MAPT 1764/4885 |
| US-20140357652-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | PKM 1453/4885L3MBTL1 3493/4885MAPT 1764/4885 |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ROCK1, ROCK2, ARHGDIA | PKM 2058/4885L3MBTL1 3539/4885MAPT 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.